 Anna Plaas
Concepts (460)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cartilage, Articular | 43 | 2017 | 586 | 4.360 |
Why?
| | Hyaluronic Acid | 22 | 2020 | 108 | 3.500 |
Why?
| | Proteoglycans | 42 | 2020 | 419 | 3.350 |
Why?
| | Aggrecans | 26 | 2020 | 200 | 2.900 |
Why?
| | ADAM Proteins | 13 | 2015 | 95 | 2.560 |
Why?
| | Osteoarthritis | 16 | 2015 | 369 | 2.270 |
Why?
| | Chondroitin Sulfates | 23 | 2018 | 42 | 2.220 |
Why?
| | Extracellular Matrix Proteins | 26 | 2019 | 176 | 2.190 |
Why?
| | Animals | 81 | 2020 | 5312 | 1.870 |
Why?
| | Glycosaminoglycans | 22 | 2017 | 69 | 1.570 |
Why?
| | Fibroblasts | 4 | 2020 | 98 | 1.520 |
Why?
| | Gene Expression Regulation | 7 | 2020 | 351 | 1.430 |
Why?
| | Osteoarthritis, Knee | 5 | 2019 | 366 | 1.380 |
Why?
| | Transforming Growth Factor beta1 | 7 | 2019 | 42 | 1.300 |
Why?
| | Wound Healing | 7 | 2020 | 175 | 1.160 |
Why?
| | Versicans | 5 | 2020 | 25 | 1.150 |
Why?
| | Horse Diseases | 2 | 2016 | 7 | 1.070 |
Why?
| | Ligaments | 2 | 2016 | 13 | 1.060 |
Why?
| | Mice, Inbred C57BL | 14 | 2020 | 548 | 1.030 |
Why?
| | Achilles Tendon | 5 | 2019 | 23 | 0.970 |
Why?
| | Endopeptidases | 6 | 2011 | 58 | 0.940 |
Why?
| | Chondrocytes | 10 | 2015 | 216 | 0.930 |
Why?
| | Mice | 19 | 2019 | 1894 | 0.930 |
Why?
| | Keratan Sulfate | 9 | 2008 | 27 | 0.910 |
Why?
| | Viscosupplements | 2 | 2012 | 13 | 0.890 |
Why?
| | Proteolysis | 2 | 2020 | 20 | 0.860 |
Why?
| | Stromal Cells | 3 | 2020 | 39 | 0.850 |
Why?
| | Glucosamine | 4 | 2009 | 15 | 0.850 |
Why?
| | Knee Injuries | 3 | 2017 | 220 | 0.830 |
Why?
| | Cattle | 29 | 2019 | 260 | 0.830 |
Why?
| | Transforming Growth Factor beta | 6 | 2016 | 126 | 0.810 |
Why?
| | Dermatan Sulfate | 8 | 2018 | 9 | 0.750 |
Why?
| | Bone and Bones | 3 | 2017 | 110 | 0.750 |
Why?
| | Fibrosis | 6 | 2017 | 53 | 0.740 |
Why?
| | Synovial Fluid | 7 | 2011 | 138 | 0.720 |
Why?
| | Glucuronosyltransferase | 2 | 2015 | 7 | 0.680 |
Why?
| | Pyridones | 1 | 2017 | 19 | 0.670 |
Why?
| | Cartilage | 12 | 2011 | 168 | 0.650 |
Why?
| | Gene Expression | 5 | 2016 | 272 | 0.640 |
Why?
| | Carrier Proteins | 8 | 2016 | 129 | 0.620 |
Why?
| | Signal Transduction | 5 | 2018 | 588 | 0.620 |
Why?
| | RNA | 1 | 2015 | 36 | 0.590 |
Why?
| | Adipose Tissue | 1 | 2016 | 98 | 0.590 |
Why?
| | Horses | 7 | 2016 | 29 | 0.580 |
Why?
| | Genome, Human | 1 | 2015 | 52 | 0.570 |
Why?
| | Tendinopathy | 4 | 2019 | 62 | 0.560 |
Why?
| | Inflammation Mediators | 1 | 2015 | 94 | 0.560 |
Why?
| | Synovial Membrane | 4 | 2012 | 79 | 0.540 |
Why?
| | Male | 27 | 2020 | 17583 | 0.530 |
Why?
| | Alpha-Globulins | 2 | 2011 | 9 | 0.520 |
Why?
| | Cells, Cultured | 16 | 2020 | 802 | 0.510 |
Why?
| | Glucose | 3 | 2019 | 76 | 0.500 |
Why?
| | Joints | 3 | 2009 | 101 | 0.490 |
Why?
| | Electrophoresis | 9 | 2010 | 23 | 0.480 |
Why?
| | Knee Joint | 5 | 2015 | 775 | 0.470 |
Why?
| | Mice, Knockout | 8 | 2018 | 399 | 0.460 |
Why?
| | Molecular Sequence Data | 13 | 2009 | 315 | 0.450 |
Why?
| | Glycoside Hydrolases | 3 | 2001 | 5 | 0.450 |
Why?
| | Biomechanical Phenomena | 11 | 2019 | 719 | 0.450 |
Why?
| | Lectins, C-Type | 14 | 2006 | 145 | 0.440 |
Why?
| | Dermis | 1 | 2011 | 8 | 0.440 |
Why?
| | Sequence Deletion | 1 | 2011 | 21 | 0.430 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 11 | 0.420 |
Why?
| | Disease Models, Animal | 9 | 2018 | 832 | 0.420 |
Why?
| | Gene Silencing | 1 | 2010 | 26 | 0.420 |
Why?
| | Stifle | 1 | 2010 | 12 | 0.420 |
Why?
| | Hyperalgesia | 1 | 2011 | 41 | 0.410 |
Why?
| | Glioma | 1 | 2010 | 58 | 0.400 |
Why?
| | Protein Biosynthesis | 6 | 1996 | 31 | 0.390 |
Why?
| | Tissue Engineering | 4 | 2019 | 50 | 0.380 |
Why?
| | Arthritis, Experimental | 1 | 2010 | 139 | 0.370 |
Why?
| | Humans | 42 | 2020 | 31481 | 0.370 |
Why?
| | Rats | 9 | 2020 | 966 | 0.360 |
Why?
| | Brain Neoplasms | 1 | 2010 | 187 | 0.360 |
Why?
| | Swine | 1 | 2008 | 117 | 0.360 |
Why?
| | Growth Plate | 4 | 2008 | 29 | 0.350 |
Why?
| | Rabbits | 13 | 2009 | 326 | 0.340 |
Why?
| | Tendons | 2 | 2018 | 212 | 0.330 |
Why?
| | Disaccharides | 5 | 2005 | 5 | 0.330 |
Why?
| | Immunohistochemistry | 5 | 2012 | 494 | 0.330 |
Why?
| | Software | 1 | 2007 | 74 | 0.320 |
Why?
| | Carbohydrate Sequence | 7 | 2001 | 15 | 0.320 |
Why?
| | Chondroitin Sulfate Proteoglycans | 6 | 2008 | 47 | 0.310 |
Why?
| | Chondrogenesis | 3 | 2020 | 30 | 0.300 |
Why?
| | Stem Cells | 2 | 2020 | 52 | 0.300 |
Why?
| | Inflammation | 2 | 2020 | 360 | 0.290 |
Why?
| | Aging | 6 | 2012 | 1614 | 0.290 |
Why?
| | beta-Galactosidase | 3 | 2001 | 9 | 0.280 |
Why?
| | Receptors, Transforming Growth Factor beta | 3 | 2016 | 10 | 0.280 |
Why?
| | Cornea | 2 | 2001 | 7 | 0.280 |
Why?
| | Models, Biological | 1 | 2007 | 428 | 0.270 |
Why?
| | Acetylglucosaminidase | 2 | 2001 | 8 | 0.270 |
Why?
| | Sulfur | 2 | 2003 | 5 | 0.260 |
Why?
| | Arthralgia | 2 | 2019 | 120 | 0.260 |
Why?
| | Polymerase Chain Reaction | 2 | 2015 | 188 | 0.250 |
Why?
| | Chondroitin Lyases | 4 | 1999 | 7 | 0.240 |
Why?
| | Chromatography, Ion Exchange | 6 | 2001 | 16 | 0.240 |
Why?
| | Molecular Weight | 3 | 2020 | 58 | 0.230 |
Why?
| | Corneal Dystrophies, Hereditary | 1 | 2001 | 1 | 0.220 |
Why?
| | Extracellular Matrix | 4 | 2015 | 92 | 0.220 |
Why?
| | Hyaluronoglucosaminidase | 2 | 2019 | 6 | 0.220 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2020 | 6 | 0.210 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2020 | 24 | 0.210 |
Why?
| | Administration, Oral | 4 | 2009 | 164 | 0.200 |
Why?
| | Scleroderma, Systemic | 1 | 2020 | 15 | 0.200 |
Why?
| | Phagocytosis | 1 | 2020 | 52 | 0.200 |
Why?
| | Endoplasmic Reticulum | 1 | 2020 | 43 | 0.200 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 34 | 0.200 |
Why?
| | Blotting, Western | 7 | 2011 | 225 | 0.200 |
Why?
| | Amino Acid Sequence | 7 | 2009 | 254 | 0.200 |
Why?
| | Medial Collateral Ligament, Knee | 1 | 2000 | 6 | 0.200 |
Why?
| | Cell Separation | 1 | 2020 | 44 | 0.200 |
Why?
| | Calcinosis | 1 | 2020 | 53 | 0.200 |
Why?
| | Lipopolysaccharides | 1 | 2020 | 138 | 0.200 |
Why?
| | Fibrillar Collagens | 1 | 2019 | 3 | 0.200 |
Why?
| | Trisaccharides | 1 | 1999 | 2 | 0.190 |
Why?
| | Rotator Cuff | 2 | 2020 | 252 | 0.190 |
Why?
| | Bursitis | 1 | 2019 | 10 | 0.190 |
Why?
| | Macrophages | 1 | 2020 | 129 | 0.190 |
Why?
| | Cell Proliferation | 1 | 2020 | 232 | 0.190 |
Why?
| | Osteolysis | 1 | 2020 | 141 | 0.190 |
Why?
| | Phenotype | 1 | 2020 | 379 | 0.180 |
Why?
| | Prostheses and Implants | 1 | 2020 | 166 | 0.180 |
Why?
| | Oligosaccharides | 4 | 2001 | 19 | 0.180 |
Why?
| | Calcaneus | 1 | 2018 | 8 | 0.180 |
Why?
| | Cattle Diseases | 1 | 1998 | 1 | 0.180 |
Why?
| | Bursa, Synovial | 1 | 2018 | 10 | 0.180 |
Why?
| | Contrast Media | 2 | 2017 | 144 | 0.180 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 14 | 0.180 |
Why?
| | Lactic Acid | 1 | 2018 | 20 | 0.180 |
Why?
| | DNA | 4 | 2015 | 139 | 0.180 |
Why?
| | Injections, Intra-Articular | 3 | 2019 | 81 | 0.180 |
Why?
| | Female | 13 | 2017 | 18253 | 0.170 |
Why?
| | Chondroitin | 3 | 2010 | 7 | 0.170 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 209 | 0.170 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2001 | 43 | 0.160 |
Why?
| | Aminopyridines | 1 | 1996 | 3 | 0.160 |
Why?
| | Chromatin | 1 | 2016 | 22 | 0.160 |
Why?
| | Pyrroles | 1 | 2016 | 22 | 0.160 |
Why?
| | Decorin | 5 | 2019 | 19 | 0.160 |
Why?
| | X-Ray Microtomography | 2 | 2017 | 71 | 0.150 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 5 | 2001 | 47 | 0.150 |
Why?
| | Protein Structure, Tertiary | 4 | 2009 | 82 | 0.150 |
Why?
| | Chondroitin ABC Lyase | 3 | 2007 | 6 | 0.150 |
Why?
| | Time Factors | 8 | 2012 | 1902 | 0.150 |
Why?
| | Pyrazoles | 1 | 2016 | 55 | 0.150 |
Why?
| | Embryo, Mammalian | 2 | 2008 | 36 | 0.150 |
Why?
| | Cyclopentanes | 1 | 1995 | 4 | 0.150 |
Why?
| | Viral Core Proteins | 1 | 1995 | 6 | 0.140 |
Why?
| | Matrix Metalloproteinase 13 | 2 | 2012 | 36 | 0.140 |
Why?
| | Chronic Disease | 2 | 2015 | 544 | 0.140 |
Why?
| | Antigens | 1 | 1995 | 29 | 0.140 |
Why?
| | DNA Methylation | 1 | 2016 | 168 | 0.140 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2011 | 30 | 0.130 |
Why?
| | Amino Sugars | 1 | 1993 | 1 | 0.130 |
Why?
| | Polysaccharides | 1 | 1993 | 20 | 0.130 |
Why?
| | Macromolecular Substances | 7 | 2005 | 24 | 0.130 |
Why?
| | Cell Aggregation | 2 | 2011 | 4 | 0.130 |
Why?
| | Histological Techniques | 1 | 1993 | 7 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2007 | 301 | 0.120 |
Why?
| | Bone Marrow Cells | 2 | 2010 | 63 | 0.120 |
Why?
| | Kinetics | 7 | 2008 | 278 | 0.120 |
Why?
| | Hydrogen-Ion Concentration | 5 | 1998 | 177 | 0.120 |
Why?
| | Injections, Intra-Arterial | 1 | 2012 | 15 | 0.120 |
Why?
| | Heparin | 2 | 2010 | 37 | 0.120 |
Why?
| | Running | 1 | 2012 | 20 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2009 | 512 | 0.120 |
Why?
| | Physical Conditioning, Animal | 2 | 2013 | 12 | 0.110 |
Why?
| | Peptide Fragments | 2 | 2008 | 122 | 0.110 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 68 | 0.110 |
Why?
| | Fibril-Associated Collagens | 1 | 2011 | 2 | 0.110 |
Why?
| | Aged | 8 | 2007 | 10295 | 0.110 |
Why?
| | Transcriptome | 1 | 2012 | 87 | 0.110 |
Why?
| | Activin Receptors | 1 | 2011 | 2 | 0.110 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 290 | 0.110 |
Why?
| | Epithelioid Cells | 1 | 2011 | 2 | 0.110 |
Why?
| | Smad Proteins, Receptor-Regulated | 1 | 2011 | 2 | 0.110 |
Why?
| | Immunoglobulin Light Chains | 1 | 2011 | 9 | 0.110 |
Why?
| | Activin Receptors, Type II | 1 | 2011 | 3 | 0.110 |
Why?
| | Activin Receptors, Type I | 1 | 2011 | 4 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2012 | 116 | 0.110 |
Why?
| | Animals, Newborn | 1 | 2011 | 77 | 0.110 |
Why?
| | Organ Size | 1 | 2011 | 122 | 0.110 |
Why?
| | Heparitin Sulfate | 3 | 2010 | 8 | 0.110 |
Why?
| | Collagen | 3 | 2018 | 111 | 0.110 |
Why?
| | Wounds and Injuries | 1 | 2011 | 58 | 0.100 |
Why?
| | Phosphorylation | 1 | 2011 | 199 | 0.100 |
Why?
| | Sulfates | 6 | 2006 | 21 | 0.100 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 60 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2010 | 217 | 0.100 |
Why?
| | Receptors, Interleukin-6 | 1 | 2009 | 7 | 0.100 |
Why?
| | Dogs | 2 | 2009 | 283 | 0.100 |
Why?
| | Hydrolysis | 2 | 2001 | 16 | 0.100 |
Why?
| | Genotype | 1 | 2011 | 423 | 0.100 |
Why?
| | Matrix Metalloproteinases, Membrane-Associated | 4 | 2016 | 11 | 0.100 |
Why?
| | Middle Aged | 8 | 2011 | 11209 | 0.090 |
Why?
| | Recovery of Function | 1 | 2011 | 309 | 0.090 |
Why?
| | Disulfides | 1 | 2009 | 17 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2009 | 23 | 0.090 |
Why?
| | Isomerism | 2 | 1999 | 3 | 0.090 |
Why?
| | Recombinant Proteins | 4 | 2019 | 295 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2009 | 120 | 0.090 |
Why?
| | Joint Capsule | 1 | 2009 | 45 | 0.090 |
Why?
| | Conserved Sequence | 1 | 2008 | 10 | 0.090 |
Why?
| | Sequence Alignment | 1 | 2008 | 29 | 0.090 |
Why?
| | Fluorescent Dyes | 2 | 2001 | 71 | 0.090 |
Why?
| | Computer Simulation | 2 | 2007 | 249 | 0.090 |
Why?
| | Apoptosis | 1 | 2010 | 292 | 0.090 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2008 | 10 | 0.090 |
Why?
| | Immune System | 1 | 2008 | 23 | 0.090 |
Why?
| | RANK Ligand | 1 | 2008 | 7 | 0.090 |
Why?
| | Stress, Mechanical | 5 | 2010 | 198 | 0.090 |
Why?
| | Osteoclasts | 1 | 2008 | 20 | 0.090 |
Why?
| | Fucose | 2 | 2001 | 2 | 0.090 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2011 | 193 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 230 | 0.090 |
Why?
| | Chromatography, Gel | 4 | 2010 | 17 | 0.090 |
Why?
| | Adolescent | 3 | 2001 | 2667 | 0.090 |
Why?
| | Cell Adhesion Molecules | 1 | 2008 | 45 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2007 | 227 | 0.090 |
Why?
| | Molecular Structure | 3 | 2003 | 32 | 0.090 |
Why?
| | Bone Remodeling | 1 | 2008 | 45 | 0.090 |
Why?
| | Osteoblasts | 1 | 2008 | 62 | 0.090 |
Why?
| | Microscopy, Atomic Force | 4 | 2010 | 10 | 0.090 |
Why?
| | Systems Biology | 1 | 2007 | 10 | 0.080 |
Why?
| | Matrix Metalloproteinases | 2 | 2006 | 31 | 0.080 |
Why?
| | Cryptococcus neoformans | 1 | 2007 | 1 | 0.080 |
Why?
| | Glycosyltransferases | 1 | 2007 | 1 | 0.080 |
Why?
| | Surface-Active Agents | 1 | 2007 | 7 | 0.080 |
Why?
| | Body Temperature | 1 | 2007 | 74 | 0.080 |
Why?
| | Gait | 1 | 2011 | 395 | 0.080 |
Why?
| | Membrane Glycoproteins | 2 | 2006 | 111 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 128 | 0.080 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2006 | 3 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 9 | 0.080 |
Why?
| | Proteins | 2 | 1991 | 94 | 0.080 |
Why?
| | Pain | 1 | 2009 | 336 | 0.080 |
Why?
| | Alkalies | 1 | 1986 | 4 | 0.080 |
Why?
| | Sulfur Radioisotopes | 4 | 1996 | 19 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2006 | 70 | 0.080 |
Why?
| | Culture Techniques | 5 | 1997 | 38 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2006 | 67 | 0.070 |
Why?
| | Vascular Diseases | 1 | 2006 | 59 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 109 | 0.070 |
Why?
| | Nanostructures | 1 | 2005 | 13 | 0.070 |
Why?
| | Biglycan | 3 | 2000 | 17 | 0.070 |
Why?
| | Models, Chemical | 1 | 2005 | 46 | 0.070 |
Why?
| | Adult | 7 | 2011 | 9779 | 0.070 |
Why?
| | Ioxaglic Acid | 2 | 2017 | 6 | 0.070 |
Why?
| | Osmolar Concentration | 1 | 2005 | 38 | 0.070 |
Why?
| | Intubation, Gastrointestinal | 1 | 2005 | 15 | 0.070 |
Why?
| | Injections, Intravenous | 1 | 2005 | 61 | 0.070 |
Why?
| | Tritium | 3 | 1996 | 16 | 0.070 |
Why?
| | Algorithms | 1 | 2007 | 412 | 0.070 |
Why?
| | Organ Culture Techniques | 3 | 1996 | 38 | 0.070 |
Why?
| | Epitopes | 3 | 2009 | 92 | 0.070 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2003 | 8 | 0.070 |
Why?
| | Metalloendopeptidases | 1 | 2003 | 38 | 0.060 |
Why?
| | Protein Binding | 4 | 2003 | 155 | 0.060 |
Why?
| | Sulfotransferases | 2 | 2003 | 7 | 0.060 |
Why?
| | Centrifugation, Density Gradient | 3 | 1989 | 15 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2003 | 79 | 0.060 |
Why?
| | Cell Membrane | 1 | 2003 | 132 | 0.060 |
Why?
| | Leucine | 2 | 1996 | 18 | 0.060 |
Why?
| | Chromatography | 2 | 1995 | 6 | 0.060 |
Why?
| | Child, Preschool | 2 | 2001 | 786 | 0.060 |
Why?
| | Chondrosarcoma | 2 | 1999 | 40 | 0.060 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2001 | 2 | 0.060 |
Why?
| | Fetus | 2 | 2000 | 63 | 0.060 |
Why?
| | Acetylglucosamine | 1 | 2001 | 2 | 0.060 |
Why?
| | Glycopeptides | 1 | 2001 | 3 | 0.060 |
Why?
| | Tail | 1 | 2001 | 4 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2001 | 36 | 0.050 |
Why?
| | P-Selectin | 1 | 2000 | 3 | 0.050 |
Why?
| | L-Selectin | 1 | 2000 | 17 | 0.050 |
Why?
| | Reference Values | 2 | 1998 | 260 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2020 | 25 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2000 | 71 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2020 | 54 | 0.050 |
Why?
| | Injections | 1 | 2019 | 59 | 0.050 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 27 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 29 | 0.050 |
Why?
| | Regeneration | 1 | 2019 | 30 | 0.050 |
Why?
| | Skin | 1 | 2000 | 136 | 0.050 |
Why?
| | Age Factors | 2 | 1997 | 943 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 183 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2020 | 281 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 2 | 2011 | 379 | 0.050 |
Why?
| | Ligaments, Articular | 1 | 2000 | 96 | 0.050 |
Why?
| | Binding Sites | 2 | 2006 | 93 | 0.040 |
Why?
| | Aerobiosis | 1 | 2018 | 2 | 0.040 |
Why?
| | Electrophoresis, Capillary | 1 | 1998 | 5 | 0.040 |
Why?
| | Antibody Specificity | 2 | 1996 | 59 | 0.040 |
Why?
| | Spectrometry, Fluorescence | 1 | 1998 | 15 | 0.040 |
Why?
| | Biological Transport | 2 | 1995 | 49 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2018 | 17 | 0.040 |
Why?
| | Nanotechnology | 2 | 2010 | 13 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 2018 | 29 | 0.040 |
Why?
| | Glycolysis | 1 | 2018 | 23 | 0.040 |
Why?
| | Carbohydrate Conformation | 1 | 1998 | 8 | 0.040 |
Why?
| | Protein Conformation | 2 | 2005 | 94 | 0.040 |
Why?
| | Random Allocation | 1 | 2018 | 164 | 0.040 |
Why?
| | Weight-Bearing | 2 | 2012 | 193 | 0.040 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 385 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 67 | 0.040 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 1997 | 10 | 0.040 |
Why?
| | Tretinoin | 1 | 1997 | 19 | 0.040 |
Why?
| | Trypsin | 1 | 2017 | 12 | 0.040 |
Why?
| | Immunoassay | 1 | 1997 | 45 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 39 | 0.040 |
Why?
| | Interleukin-1 | 1 | 1997 | 91 | 0.040 |
Why?
| | Glycoproteins | 1 | 1997 | 65 | 0.040 |
Why?
| | Monosaccharides | 1 | 1996 | 2 | 0.040 |
Why?
| | Chondroitinases and Chondroitin Lyases | 2 | 2010 | 6 | 0.040 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2016 | 4 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 24 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 28 | 0.040 |
Why?
| | Cycloheximide | 1 | 1996 | 12 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 60 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 108 | 0.040 |
Why?
| | Brain | 1 | 2006 | 1655 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2019 | 3910 | 0.040 |
Why?
| | Brefeldin A | 1 | 1995 | 3 | 0.040 |
Why?
| | Golgi Apparatus | 1 | 1995 | 7 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1995 | 12 | 0.040 |
Why?
| | Procollagen N-Endopeptidase | 2 | 2007 | 30 | 0.040 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 2 | 0.040 |
Why?
| | Cell Line | 2 | 2008 | 360 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2015 | 8 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2015 | 12 | 0.040 |
Why?
| | Abdominal Fat | 1 | 2015 | 12 | 0.040 |
Why?
| | Syndecans | 2 | 2006 | 5 | 0.040 |
Why?
| | Infant | 1 | 1997 | 642 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 315 | 0.040 |
Why?
| | Syndecan-1 | 2 | 2006 | 10 | 0.040 |
Why?
| | Ribs | 1 | 1995 | 19 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 42 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 148 | 0.030 |
Why?
| | Mannosidases | 1 | 1993 | 1 | 0.030 |
Why?
| | alpha-Mannosidase | 1 | 1993 | 1 | 0.030 |
Why?
| | Hydroxyproline | 2 | 2010 | 7 | 0.030 |
Why?
| | Collagen Type III | 1 | 2013 | 14 | 0.030 |
Why?
| | Collagen Type I | 1 | 2013 | 19 | 0.030 |
Why?
| | Integrins | 1 | 2013 | 27 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 2003 | 248 | 0.030 |
Why?
| | Tibia | 1 | 1995 | 266 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2006 | 371 | 0.030 |
Why?
| | Hindlimb | 1 | 2012 | 31 | 0.030 |
Why?
| | Transfection | 2 | 2003 | 154 | 0.030 |
Why?
| | Polysaccharide-Lyases | 1 | 2010 | 5 | 0.030 |
Why?
| | Tunicamycin | 1 | 1990 | 3 | 0.030 |
Why?
| | Peptide Mapping | 1 | 1990 | 8 | 0.030 |
Why?
| | Glycosylation | 1 | 1990 | 22 | 0.030 |
Why?
| | Amino Acids | 1 | 1990 | 26 | 0.030 |
Why?
| | Models, Molecular | 1 | 1990 | 99 | 0.030 |
Why?
| | Models, Animal | 1 | 2010 | 149 | 0.030 |
Why?
| | Hydrogels | 1 | 2010 | 9 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 1989 | 8 | 0.020 |
Why?
| | Ankle Injuries | 1 | 2009 | 11 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 88 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2009 | 12 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 13 | 0.020 |
Why?
| | Streptomyces | 1 | 1989 | 2 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2009 | 39 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 181 | 0.020 |
Why?
| | Silver Staining | 1 | 2009 | 6 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 43 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 265 | 0.020 |
Why?
| | Antibodies | 1 | 2009 | 72 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2008 | 6 | 0.020 |
Why?
| | Hedgehog Proteins | 1 | 2008 | 13 | 0.020 |
Why?
| | Femur | 1 | 2012 | 389 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2008 | 46 | 0.020 |
Why?
| | Peptides | 1 | 2009 | 116 | 0.020 |
Why?
| | Bone Morphogenetic Protein 2 | 1 | 2008 | 45 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 191 | 0.020 |
Why?
| | Bone Resorption | 1 | 2008 | 96 | 0.020 |
Why?
| | Escherichia | 1 | 2007 | 1 | 0.020 |
Why?
| | Proline | 3 | 1994 | 22 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2007 | 8 | 0.020 |
Why?
| | Biological Assay | 1 | 2007 | 9 | 0.020 |
Why?
| | Virulence | 1 | 2007 | 13 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 378 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2008 | 100 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 2007 | 21 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2007 | 8 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2007 | 6 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2007 | 14 | 0.020 |
Why?
| | Serum Albumin, Bovine | 1 | 2007 | 9 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2008 | 308 | 0.020 |
Why?
| | Liposomes | 1 | 2007 | 23 | 0.020 |
Why?
| | Paraffin Embedding | 1 | 2007 | 5 | 0.020 |
Why?
| | Tissue Fixation | 1 | 2007 | 11 | 0.020 |
Why?
| | Cats | 1 | 2007 | 79 | 0.020 |
Why?
| | Formaldehyde | 1 | 2007 | 14 | 0.020 |
Why?
| | Pain Measurement | 1 | 2009 | 476 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2007 | 83 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2007 | 140 | 0.020 |
Why?
| | Hyperplasia | 1 | 2006 | 26 | 0.020 |
Why?
| | Carbohydrate Metabolism | 1 | 2006 | 8 | 0.020 |
Why?
| | Osteogenesis | 1 | 2007 | 94 | 0.020 |
Why?
| | Tunica Intima | 1 | 2006 | 33 | 0.020 |
Why?
| | Microcirculation | 1 | 2006 | 40 | 0.020 |
Why?
| | Methylene Blue | 1 | 1986 | 4 | 0.020 |
Why?
| | Arthritis | 1 | 2007 | 113 | 0.020 |
Why?
| | Half-Life | 1 | 1986 | 19 | 0.020 |
Why?
| | Protein Denaturation | 1 | 1985 | 4 | 0.020 |
Why?
| | Methods | 1 | 1985 | 25 | 0.020 |
Why?
| | Bone Density | 1 | 2007 | 141 | 0.020 |
Why?
| | Hot Temperature | 1 | 1985 | 26 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 87 | 0.020 |
Why?
| | Collagen Type II | 1 | 2005 | 36 | 0.020 |
Why?
| | Prospective Studies | 1 | 2011 | 1934 | 0.020 |
Why?
| | Elasticity | 1 | 2005 | 53 | 0.020 |
Why?
| | Static Electricity | 1 | 2005 | 45 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 52 | 0.020 |
Why?
| | DNA Primers | 1 | 2005 | 64 | 0.020 |
Why?
| | Base Sequence | 1 | 2005 | 166 | 0.020 |
Why?
| | Anterior Cruciate Ligament | 1 | 2007 | 268 | 0.020 |
Why?
| | Biocompatible Materials | 1 | 2005 | 112 | 0.020 |
Why?
| | Cell Division | 1 | 1984 | 122 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 4 | 0.020 |
Why?
| | Endopeptidase K | 1 | 2003 | 6 | 0.020 |
Why?
| | Precipitin Tests | 1 | 2003 | 15 | 0.020 |
Why?
| | Type C Phospholipases | 1 | 2003 | 11 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2003 | 29 | 0.020 |
Why?
| | Chromatography, Affinity | 1 | 1983 | 11 | 0.020 |
Why?
| | Particle Size | 1 | 2003 | 71 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2003 | 91 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 2277 | 0.010 |
Why?
| | Hydrostatic Pressure | 2 | 1994 | 7 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 464 | 0.010 |
Why?
| | Biotinylation | 1 | 2000 | 2 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 2000 | 17 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 39 | 0.010 |
Why?
| | Latent TGF-beta Binding Proteins | 1 | 2000 | 1 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2000 | 155 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2000 | 50 | 0.010 |
Why?
| | Cicatrix | 1 | 2000 | 13 | 0.010 |
Why?
| | Pressure | 2 | 1991 | 71 | 0.010 |
Why?
| | Gestational Age | 1 | 2000 | 100 | 0.010 |
Why?
| | Down-Regulation | 1 | 2000 | 134 | 0.010 |
Why?
| | Up-Regulation | 1 | 2000 | 220 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2001 | 580 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 494 | 0.010 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 1997 | 7 | 0.010 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 1997 | 7 | 0.010 |
Why?
| | Dipeptides | 1 | 1997 | 7 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1997 | 21 | 0.010 |
Why?
| | Electrophysiology | 1 | 1997 | 140 | 0.010 |
Why?
| | Molecular Biology | 1 | 1995 | 14 | 0.010 |
Why?
| | Species Specificity | 1 | 1995 | 78 | 0.010 |
Why?
| | Gap Junctions | 1 | 1995 | 23 | 0.010 |
Why?
| | Autoradiography | 1 | 1994 | 13 | 0.010 |
Why?
| | Physical Stimulation | 1 | 1994 | 17 | 0.010 |
Why?
| | Diffusion | 1 | 1994 | 28 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1994 | 87 | 0.010 |
Why?
| | Menisci, Tibial | 1 | 1995 | 166 | 0.010 |
Why?
| | RNA, Transfer, Pro | 1 | 1989 | 2 | 0.010 |
Why?
| | Hexuronic Acids | 1 | 1984 | 12 | 0.000 |
Why?
|
|
Plaas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|